Drug Discovery Opinion

Prostate cancer is the most common cancer among men, and it has been estimated that up to 10,000 men in the UK are diagnosed each year with the most aggressive form of the disease. A small scale clinical trial has now shown that abiraterone is able to shrink prostate cancer tumours in patients who have not responded to alternative medical or surgical treatments. Abiraterone works by inhibiting production of male hormones, which can stimulate the growth of prostate cancer cells, throughout the body and not just in the testes.

Many of men on the trial reported significant improvements in their quality of life and some were able to stop taking morphine for control of pain caused by the cancer spreading into their bones.

Bookmark It

Hide Sites

Related posts:

1. HIV drugs could treat prostate cancer and CFS – if they are caused by XMRV The retrovirus, xenotropic murine leukemia virus-related virus (XMRV), has been – controversially – linked to both prostate cancer and chronic...
2. Prostate Cancer and NSAID Use Prostate cancer is the most common cancer in men, with the majority of cases occurring in the over-65s. Rising levels...
3. Two New Potential Biomarkers for Prostate Cancer Although prostate cancer is one of the most common types of cancer in men, it occurs most frequently after the...
4. Retrovirus Linked to Prostate Cancer A number of human cancers are linked to viral infection including cervical cancer (human papilloma virus), liver cancer (hepatitis B...
5. Targeting ‘Normal’ Cells to Treat Cancer Most cancer treatments directly target the cancerous cells but tumours are a heterogeneous mix of transformed cells and ‘normal’ cells....

Related posts brought to you by Yet Another Related Posts Plugin.

 Email This Post

This entry was posted on Tuesday, July 22nd, 2008 at 8:43 pm and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.